Search Results - "Shackleford, Terry J."

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    JAB1/CSN5: a new player in cell cycle control and cancer by Shackleford, Terry J, Claret, Francois X

    Published in Cell division (18-10-2010)
    “…c-Jun activation domain-binding protein-1 (Jab1) acts as a modulator of intracellular signaling and affects cellular proliferation and apoptosis, through its…”
    Get full text
    Journal Article
  2. 2

    Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells by Shackleford, Terry J, Zhang, Qingxiu, Tian, Ling, Vu, Thuy T, Korapati, Anita L, Baumgartner, Angela M, Le, Xiao-Feng, Liao, Warren S, Claret, Francois X

    Published in Breast cancer research : BCR (20-06-2011)
    “…The c-Jun coactivator, Jun activation-domain binding protein 1 (Jab1) also known as the fifth component of the COP9 signalosome complex (CSN5), is a novel…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Abstract 5825: Mechanisms of intrinsic and acquired resistance to antibodies targeting IGF-1R in pediatric sarcoma cell lines by Shackleford, Terry J., Hariharan, Seethalakshmi, Phelps, Doris, Bid, Hemant, Zhong, Hiahong, Houghton, Peter

    Published in Cancer research (Chicago, Ill.) (01-07-2017)
    “…Abstract Background: Pediatric bone and soft tissue sarcomas are heavily dependent on the Type 1 insulin-like growth factor receptor (IGF-1R) signaling axis,…”
    Get full text
    Journal Article
  8. 8

    Abstract 2472: Mechanisms of resistance to IGFR-targeted therapy in pediatric sarcomas by Shackleford, Terry J., Hariharan, Seethalakshmi, Bid, Hemant K., Houghton, Peter J.

    Published in Cancer research (Chicago, Ill.) (15-07-2016)
    “…Abstract Background: Insulin-like growth factor-I receptor (IGFR) signaling promotes tumorigenic properties which makes targeting IGFR an attractive…”
    Get full text
    Journal Article
  9. 9

    Abstract 1825: Jab1/Csn5 a new target in the resistant mechanism to HER2-targeted therapies for breast cancer by Claret, Francois X., Vu, Thuy, Shackleford, Terry J., Allensworth, Jennifer, Zhang, Qingxiu, Tian, Ling, Zhang, Ronghua

    Published in Cancer research (Chicago, Ill.) (01-10-2014)
    “…Abstract Her2 positive (Her2+) breast cancer (BC) accounts for 20% of all breast cancer subtypes and is associated with high risk of death. Trastuzumab (Ttzm),…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Abstract B231: Jab1/Csn5 a new player driving the resistance to Her2-targeted therapies for breast cancer by Vu, Thuy T., Shackleford, Terry J., Zhang, Qingxiu, Esteva, Francisco J., Drakos, Elias, Tian, Ling, Kute, Timothy, Sahin, Aysegul A., Rassidakis, George Z., Claret, Francois X.

    Published in Molecular cancer therapeutics (01-11-2013)
    “…Abstract Her2 a key member in the epidermal growth factor receptor (EGFR) family, is one of the most dominant oncogenes in breast cancer. It is overexpressed…”
    Get full text
    Journal Article
  12. 12